Home » Stocks » EW

Edwards Lifesciences Corporation (EW)

Stock Price: $92.17 USD 0.42 (0.46%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 57.04B
Revenue (ttm) 4.47B
Net Income (ttm) 851.00M
Shares Out 623.20M
EPS (ttm) 1.35
PE Ratio 68.32
Forward PE 42.19
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $92.17
Previous Close $91.75
Change ($) 0.42
Change (%) 0.46%
Day's Open 91.87
Day's Range 91.80 - 93.67
Day's Volume 2,255,078
52-Week Range 66.23 - 98.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendat...

2 days ago - PRNewsWire

Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ...

2 weeks ago - Zacks Investment Research

Edwards Lifesciences Corp. (NYSE:EW) and Intuitive Surgical Inc. (NASDAQ:ISRG) are on the Wall Street radar this week.

Other stocks mentioned: ISRG
2 weeks ago - GuruFocus

ORANGE COUNTY, Calif., April 21, 2021 /PRNewswire/ -- Providence, a national nonprofit health system, is partnering with Edwards Lifesciences (NYSE: EW), the Orange County-based medical technology compa...

2 weeks ago - PRNewsWire

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.

2 weeks ago - Zacks Investment Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 14.89% and 4.93%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Shares of Edwards Lifesciences (NYSE:EW) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 64.24% year over year to $0.54, which beat ...

2 weeks ago - Benzinga

IRVINE, Calif., April 20, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2021.

2 weeks ago - PRNewsWire

Edwards Lifesciences (NYSE:EW) releases its next round of earnings this Tuesday, April 20. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.

2 weeks ago - Benzinga

With the trading day about halfway over, the broad markets were pushing much higher with solid gains across the board.

Other stocks mentioned: AMD, BSX, INTC, NVDA, AEO, CAKE, CBRL
3 weeks ago - 24/7 Wall Street

Learning to fly an airplane can build an excellent structured thought process for navigating markets.

Other stocks mentioned: ARKX, BA, SPCE, UAL
3 weeks ago - Zacks Investment Research

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.

3 weeks ago - Zacks Investment Research

IRVINE, Calif., April 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2021 after the market closes on Tuesday, April 20, ...

3 weeks ago - PRNewsWire

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway Inc. (NYSE:BRK.A)(NYSE:BRK.B) disclosed on Tuesday its fourth-quarter 2020 portfolio, revealing new holdings in Verizon Inc. (NYSE:VZ), Chevron Co...

Other stocks mentioned: AAPL, CVX, JPM, VZ
2 months ago - GuruFocus

AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards' bioprosthetic surgical aortic valve with ...

3 months ago - PRNewsWire

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust performances in TMTT business in Q4.

3 months ago - Zacks Investment Research

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q4 2020 Results - Earnings Call Transcript

3 months ago - Seeking Alpha

While technology stocks remain hot in 2021, there are other sectors that should be on your radar this earnings season.

Other stocks mentioned: CAT, LRCX, SHW, URI
3 months ago - Zacks Investment Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -5.66% and 0.71%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Edwards Lifesciences (NYSE:EW) decreased 4.5% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 65.75% over the past year to $0.50, ...

3 months ago - Benzinga

IRVINE, Calif., Jan. 27, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2020. Fourth Quarter Highlights and Outlook Q4 sales inc...

3 months ago - PRNewsWire

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

3 months ago - Zacks Investment Research

IRVINE, Calif., Jan. 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2020 after the market closes on Wednesday, Januar...

3 months ago - PRNewsWire

Edwards Lifesciences is a quality name that sits at the tip of the spear in cardiovascular value procedure offerings. The company has remained resilient in the face of the pandemic, and is well position...

3 months ago - Seeking Alpha

IRVINE, Calif., Dec. 21, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW), today announced that the first patient has been treated in the RESTORE clinical trial, which will evaluate the safety and e...

4 months ago - PRNewsWire

Edwards Lifesciences CEO on the state of elective surgeries amid pandemic

YouTube video

Edward Lifesciences CEO Mike Mussallem explained why he is concerned about how patients with structural heart disease are being treated for health issues as hospitals are overwhelmed by Covid-19 patients.

4 months ago - CNBC Television

IRVINE, Calif., Dec. 10, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and sha...

4 months ago - PRNewsWire

ESG investing can help create value both for society and shareholders. These seven ESG stocks are a good place to start.

Other stocks mentioned: CNHI, HAS, MSFT, NEE, OC, PLD
5 months ago - InvestorPlace

There are many useful nooks and crannies on the GuruFocus website, including screeners that help us find stocks outside the mainstream.

Other stocks mentioned: FNV, MASI
6 months ago - GuruFocus

Strong Q3 exit with +6.4% growth in TAVR therapy sales, in spite of pressures from COVID-19. Shareholders have enjoyed +70% gains since March, however, with high volatility to the downside, which needs ...

6 months ago - Seeking Alpha

In this article we will take a look at whether hedge funds think Edwards Lifesciences Corporation (NYSE:EW) is a good investment right now. We check hedge fund and billionaire investor sentiment before ...

6 months ago - Insider Monkey

Edwards expects to resume double digit growth as a robust product pipeline gets to market

6 months ago - Forbes

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q3.

6 months ago - Zacks Investment Research

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 13.33% and 5.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Edwards Lifesciences late Wednesday posted third-quarter sales that edged expectations and earnings per share that beat, but it hiked its earnings outlook only slightly and EW stock fell. The post Edwar...

6 months ago - Investors Business Daily

Shares of Edwards Lifesciences (NYSE:EW) decreased 2.5% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 63.83% year over year to $0.51, whic...

6 months ago - Benzinga

IRVINE, Calif., Oct. 21, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2020. Third Quarter Highlights and Outlook Sales of $1....

6 months ago - PRNewsWire

These popular stocks have some of the best earnings charts of the week.

Other stocks mentioned: CMG, DHR, TSLA, WHR
6 months ago - Zacks Investment Research

On Wednesday, October 21, Edwards Lifesciences (NYSE: EW) will release its latest earnings report. Here is Benzinga's outlook for the company.

6 months ago - Benzinga

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Robust customer adoption of the TruWave disposable pressure monitoring devices and the INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q3 revenues.

6 months ago - Zacks Investment Research

IRVINE, Calif., Oct. 7, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW), plans to announce its operating results for the quarter ended September 30, 2020 after the market closes on Wednesday, Octob...

7 months ago - PRNewsWire

According to the All-in-One Screener, a Premium feature of GuruFocus, five stalwarts that have high financial strength and expanding operating margins include Mastech Digital Inc. (MHH), Columbia Sports...

Other stocks mentioned: COLM, MASI, MED, MHH
7 months ago - GuruFocus

Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.

Other stocks mentioned: ISRG, BSX, GH, NVCR
8 months ago - Investors Business Daily

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

TMO vs. EW: Which Stock Is the Better Value Option?

Other stocks mentioned: TMO
9 months ago - Zacks Investment Research

Health care is supposed to be a very defensive sector in investing. After all, diseases and conditions such as cancer, diabetes, heart disease, kidney failure, dementia, joint damage and spinal issues a...

Other stocks mentioned: ABT, BAX, BSX, GMED, JNJ, MDT, NUVA ...
9 months ago - 24/7 Wall Street

About EW

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve re... [Read more...]

Industry
Medical Devices
IPO Date
Mar 27, 2000
CEO
Michael Mussallem
Employees
14,900
Stock Exchange
NYSE
Ticker Symbol
EW
Full Company Profile

Financial Performance

In 2020, EW's revenue was $4.39 billion, an increase of 0.88% compared to the previous year's $4.35 billion. Earnings were $823.40 million, a decrease of -21.35%.

Financial Statements

Analyst Forecasts

According to 25 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is 98.35, which is an increase of 6.71% from the latest price.

Price Target
$98.35
(6.71% upside)
Analyst Consensus: Buy